Switch studies in virologically suppressed patients

Switch to DRV/ r + 3TC
DUAL Study
Original article : Pulido F, HIV Drug Therapy 2016, Glasgow, O331
Last update : 02/01/2017

Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK

  • Dual therapy with DRV/r plus 3TC was non-inferior regarding maintenance of viral suppression and equally well tolerated as DRV/r plus TDF/FTC (or ABC/3TC)
  • Persistent virological suppression was maintained after switching to dual therapy with DRV/r plus 3TC
  • These results reinforce the efficacy of dual therapy with a fully active boosted PI and 3TC for maintenance of virological suppression

Design


* Randomisation was stratified by baseline nucleos (t)ides

Objective

  • Primary Endpoint: proportion with treatment success (HIV RNA < 50 c/mL) at W48, ITTe , snapshot

Baseline characteristics and disposition at W48

Efficacy and Safety results (W48)

 

Back to Table of Contents

Copyright AEI 2017 | Links | Contact | Faculty and Disclosure | Terms of use aei